What do systematic reviews say?

Rituximab (B cell) + steroid vs steroids

• Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 58 participants
  High

Rituximab (B cell) + steroid vs steroids

Rituximab (B cell) + steroid probably leads to higher treatment adverse events: UTI/pyelonephritis compared with steroid alone (moderate certainty).

• Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 5.73 [1.8, 18.21]
  1 study · 38 participants
  Moderate

Antibody (T cell) + steroid vs steroids

It is very uncertain whether antibody (T cell) + steroid changes graft loss or death with a functioning graft compared with steroid alone (very low certainty).

• Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.35 [0.02, 5.14]
  2 studies · 52 participants
  Very low

Scheduled surveillance vs clinical monitoring alone

Scheduled surveillance showed no clear difference in risk of access thrombosis compared with clinical monitoring alone (moderate certainty).

• Pre‐emptive correction for haemodialysis arteriovenous access stenosis 2016 · Cochrane Headline outcomes only
  RR 0.95 [0.8, 1.12]
  8 studies · 697 participants
  Moderate

Scheduled surveillance vs clinical monitoring alone

Scheduled surveillance may leads to higher rate of angiograms compared with clinical monitoring alone (low certainty).

• Pre‐emptive correction for haemodialysis arteriovenous access stenosis 2016 · Cochrane Headline outcomes only
  RR 1.78 [1.18, 2.67]
  5 studies · 539 participants
  Low

Scheduled surveillance vs clinical monitoring alone

Scheduled surveillance showed no clear difference in risk of access loss compared with clinical monitoring alone (moderate certainty).

• Pre‐emptive correction for haemodialysis arteriovenous access stenosis 2016 · Cochrane Headline outcomes only
  RR 0.9 [0.71, 1.15]
  6 studies · 662 participants
  Moderate

Scheduled surveillance vs clinical monitoring alone

Scheduled surveillance showed no clear difference in mortality compared with clinical monitoring alone (low certainty).

• Pre‐emptive correction for haemodialysis arteriovenous access stenosis 2016 · Cochrane Headline outcomes only
  RR 1.38 [0.9, 2.11]
  5 studies · 586 participants
  Low